This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

Antibody Engineering & Therapeutics Europe
6 - 8 June, 2023
Postillon Hotel AmsterdamDigital Experience: All Sessions Live-streamed 6-8 June, 2023

Deepali Sawant
Scientist at Amgen

Profile

Deepali Sawant is currently a Principal Scientist at Amgen San Francisco, where she leads a Pharmacology group that delivers preclinical in vivo data to support the oncology pipeline. Prior to joining Amgen in 2017, Deepali conducted postdoctoral studies in the laboratory of Dario Vignali at the University of Pittsburgh and St. Jude Children’s Research Hospital where she worked on elucidating the role of regulatory T cells and inhibitory cytokines in anti-tumor immunity. She received her PhD in Immunology at Indiana University studying transcriptional regulation of regulatory T cell stability in the context of autoimmune and inflammatory diseases. She has authored 20 publications, including 13 first/co-first-author research articles and reviews in high impact peer-reviewed journals.

Agenda Sessions

  • Agonistic Bispecific Antibody Selectively Targeting IL-2Rβγ for Treatment of Solid Tumors

    08:50